Aligos Therapeutics, Inc.ALGSNASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank57
3Y CAGR-19.0%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
-19.0%/yr
Annual compound
Percentile
P57
Within normal range
vs 3Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 36.17 | -35.4% |
| 2024 | 56.01 | +201.7% |
| 2023 | 18.57 | -72.8% |
| 2022 | 68.18 | -97.4% |
| 2021 | 2673.72 | - |
| 2020 | 0.00 | - |
| 2019 | 0.00 | - |
| 2018 | 0.00 | - |